Archive

ESOT 2015: Tailor-made immunosuppression and post-transplant follow-up

by Maria Dalby: Advances in diagnostic techniques, genetic testing and immunosuppressive protocols allow clinicians to tailor interventions to the individual patient’s needs to a greater extent than in… read more.

IMV 2015: Newly diagnosed multiple myeloma, elderly patients: Professor Gareth Morgan, (Little Rock, USA) and Professor Paul Richardson, (Boston, USA) discuss managing older patients with MM

The majority of patients presenting with MM are elderly and pose a considerable clinical challenge in terms of disease burden and comorbidities compared with their younger counterparts. A… read more.

IMV 2015: Activated pathways leading to high-risk myeloma: Professor Gareth Morgan, UAMS Myeloma Institute, Arkansas, USA discusses how our understanding of the biological pathways in MM has progressed recently.

Gene expression profiling (GEP) is currently the best approach for defining risk in multiple myeloma (MM). Mutation detection may be used for improving risk stratification and providing additional… read more.

IMV 2015: Dr Noopar Raje (Massachusetts General Hospital Cancer Center, Boston.) discusses the key points from this practical session on what is difficult about treating bone disease.

IMV 2015 Debate: Professors Faith Davies, Gareth Morgan (both UAMS) and Sagar Lonial (Atlanta) discuss the importance of combination therapy. Professor Faith Davies from UAMS and Professor Shaji Kumar from Mayo Clinic faced one another in a debate over the respective benefits of combination therapy and sequential therapy in MM…

Specialists in the MM field are in the enviable position of having lots of different treatment options available – the challenge is how to integrate these into the… read more.

IMV 2015: New diagnostic criteria for multiple myeloma

Multiple myeloma is unique amongst cancers in that the diagnosis is made by the clinician, not the pathologist. The pathologist merely states that the patient has a clonal… read more.

Investigative vaccine eradicates precancerous lesions in some women

by Bruce Sylvester: Researchers report that a genetically engineered vaccine, VGX-3100/ Inovio Pharmaceuticals,  appears to eradicate high-grade precancerous cervical lesions in some women. The findings from a phase 2b… read more.

Androgen deprivation therapy problematic for prior heart attack victims

by Bruce Sylvester: Men who have had a heart attack and then receive androgen deprivation therapy (ADT) for prostate cancer are at an increased risk of subsequent fatal… read more.

World Health Matters: Exercise helps women tolerate chemotherapy

by Gary Finnegan: Netherlands: Women with breast cancer who follow a physical exercise programme during their chemotherapy treatment experience fewer side effects, according a study by the Netherlands… read more.

EMA Highlights: Green light for new medicines

by Gary Finnegan: The European Medicines Agency’s key committee approved a total of 19 new medicines at its meeting in late September – the highest number of products… read more.

Can asthma protect men from lethal prostate cancer?

Men with asthma are less likely to have aggressive prostate cancer or to die from the disease, according to a large, prospective cohort study published in the International… read more.

USA pain by the numbers

In one of the largest population studies on pain to date, researchers with the National Institutes of Health estimate that nearly 40 million Americans experience severe pain and… read more.